Nanocarrier System for Increasing the Therapeutic Efficacy of Oxaliplatin.

The application of Oxaliplatin (OxPt) in different malignancies is reported to be accompanied by several side effects including neuropathy, nausea, vomiting, diarrhea, mouth sores, low blood counts, loss of appetite, etc. The passive or active targeting of different tumors can improve OxPt delivery. Considering the demand for novel systems meant to improve the OxPt efficacy and define the shortcomings, we provided an overview of different approaches regarding the delivery of OxPt. There is an extending body of data that exhibits the value of Liposomes and polymer-based drug delivery systems as the most successful systems among the OxPt drug delivery procedures. Several clinical trials have been carried out to investigate the side effects and dose-limiting toxicity of liposomal oxaliplatin such as the assessment on Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors. In addition, several studies indicated the biocompatibility and biodegradability of this product, as well as its option for being fictionalized to derive specialized smart nanosystems for the treatment of cancer. The better delivery of OxPt with weaker side effects could be generated by the exertion of Oxaliplatin, which involves the aggregation of new particles and multifaceted nanocarriers to compose a nanocomposite with both inorganic and organic nanoparticles.

• Publication year

  2022

• Venue

  Current Cancer Drug Targets

• Publication date

  2022-01-20

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.2174/1568009622666220120115140PMID 35048809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cocktail strategy for 'cold' tumors therapy via active recruitment of CD8+ T cells and enhancing their function.

  2021cited by this paper
• Oxygen and oxaliplatin-loaded nanoparticles combined with photo-sonodynamic inducing enhanced immunogenic cell death in syngeneic mouse models of ovarian cancer.

  2021cited by this paper
• PrPC Aptamer Conjugated–Gold Nanoparticles for Targeted Delivery of Doxorubicin to Colorectal Cancer Cells

  2021cited by this paper
• Poly(Ethylene Glycol)-b-Poly(D,L-Lactide) Nanoparticles as Potential Carriers for Anticancer Drug Oxaliplatin

  2021cited by this paper
• In vitro and in vivo combinatorial anticancer effects of oxaliplatin- and resveratrol-loaded N,O-carboxymethyl chitosan nanoparticles against colorectal cancer.

  2021cited by this paper
• Nano-evolution and protein-based enzymatic evolution predicts novel types of natural product nanozymes of traditional Chinese medicine: cases of herbzymes of Taishan-Huangjing (Rhizoma polygonati) and Goji (Lycium chinense)

  2021cited by this paper
• 99mTc-labelled and pH-awakened microbeads entrapping surface-modified lipid nanoparticles for the augmented effect of oxaliplatin in the therapy of colorectal cancer

  2020cited by this paper
• Localized and triggered release of oxaliplatin for the treatment of colorectal liver metastasis

  2020cited by this paper
• Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy

  2020cited by this paper
• Preparation and Evaluation of Intraperitoneal Long-Acting Oxaliplatin-Loaded Multi-Vesicular Liposomal Depot for Colorectal Cancer Treatment

  2020cited by this paper
• Biomimetic Magnetoliposomes as Oxaliplatin Nanocarriers: In Vitro Study for Potential Application in Colon Cancer

  2020cited by this paper
• Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy

  2020cited by this paper
• Liposome-Embedding Silicon Microparticle for Oxaliplatin Delivery in Tumor Chemotherapy

  2020cited by this paper
• Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin αII-Overexpressing Ovarian Carcinoma

  2020cited by this paper
• Effect of Oxaliplatin-Loaded Poly (d,l-Lactide-co-Glycolic Acid) (PLGA) Nanoparticles Combined with Retinoic Acid and Cholesterol on Apoptosis, Drug Resistance, and Metastasis Factors of Colorectal Cancer

  2020cited by this paper
• Improvement of efficacy and decrement cytotoxicity of oxaliplatin anticancer drug using bovine serum albumin nanoparticles: synthesis, characterisation and release behaviour.

  2020cited by this paper
• Maximizing the potency of oxaliplatin coated nanoparticles with folic acid for modulating tumor progression in colorectal cancer.

  2020cited by this paper
• Smart Nanocarriers for the Delivery of Nucleic Acid‐Based Therapeutics: A Comprehensive Review

  2020cited by this paper
• Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview

  2019cited by this paper
• Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivo.

  2019cited by this paper
• Co-delivery of 5-fluorouracil and oxaliplatin in novel poly(3-hydroxybutyrate-co-3-hydroxyvalerate acid)/poly(lactic-co-glycolic acid) nanoparticles for colon cancer therapy.

  2019cited by this paper
• Folate conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor and apoptosis efficacy on colorectal cancer cells (HT29 cell line).

  2019cited by this paper
• Pharmacokinetic Profile and Anti-Adhesive Effect of Oxaliplatin-PLGA Microparticle-Loaded Hydrogels in Rats for Colorectal Cancer Treatment

  2019cited by this paper
• MiRNA-204-5p and oxaliplatin-loaded silica nanoparticles for enhanced tumor suppression effect in CD44-overexpressed colon adenocarcinoma.

  2019cited by this paper
• Target-specific delivery of oxaliplatin to HER2-positive gastric cancer cells in vivo using oxaliplatin-au-fe3o4-herceptin nanoparticles.

  2018cited by this paper
• Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.

  2018cited by this paper
• Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation

  2018cited by this paper
• The side effects of platinum-based chemotherapy drugs: a review for chemists.

  2018cited by this paper
• Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model

  2017cited by this paper
• Factors associated with the development and severity of oxaliplatin‐induced peripheral neuropathy: a systematic review

  2017cited by this paper
• Revisiting the use of sPLA2‐sensitive liposomes in cancer therapy

  2017cited by this paper
• Co‐administration of liposomal l‐OHP and PEGylated TS shRNA‐lipoplex: A novel approach to enhance anti‐tumor efficacy and reduce the immunogenic response to RNAi molecules

  2017cited by this paper
• Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity

  2017cited by this paper
• Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer.

  2017cited by this paper
• Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo.

  2017cited by this paper
• Drug Delivery Strategies for Platinum-Based Chemotherapy.

  2017cited by this paper
• Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors

  2016cited by this paper
• Design of a novel theranostic nanomedicine: synthesis and physicochemical properties of a biocompatible polyphosphazene–platinum(II) conjugate

  2016cited by this paper
• Platinum-based drugs: past, present and future

  2016cited by this paper
• Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles

  2016cited by this paper
• Formulation and optimization of oxaliplatin immuno-nanoparticles using Box–Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer

  2016cited by this paper
• Preparation and evaluation of liver-targeting micelles loaded with oxaliplatin

  2016cited by this paper
• Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer.

  2016cited by this paper
• The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

  2016cited by this paper
• Multiplexed Dosing Assays by Digitally Definable Hydrogel Volumes

  2016cited by this paper
• Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

  2015cited by this paper
• Intra-tumor distribution of PEGylated liposome upon repeated injection: No possession by prior dose.

  2015cited by this paper
• Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.

  2015cited by this paper
• Oxaliplatin-chitosan nanoparticles induced intrinsic apoptotic signaling pathway: a "smart" drug delivery system to breast cancer cell therapy.

  2014cited by this paper
• Synthesis and properties of a new micellar polyphosphazene-platinum(II) conjugate drug.

  2014cited by this paper
• Synthesis of mesoporous silica nanoparticle-oxaliplatin conjugates for improved anticancer drug delivery.

  2014cited by this paper
• PEG-liposomal oxaliplatin combined with nuclear factor-κB inhibitor (PDTC) induces apoptosis in human colorectal cancer cells.

  2014cited by this paper
• Bovine serum albumin nanoparticles as controlled release carrier for local drug delivery to the inner ear

  2014cited by this paper
• Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.

  2014cited by this paper
• Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2

  2013cited by this paper
• Nanocarriers for delivery of platinum anticancer drugs.

  2013cited by this paper
• Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: Results from a prospective multicenter study

  2013cited by this paper
• Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

  2013cited by this paper
• Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.

  2013cited by this paper
• Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

  2012cited by this paper
• Literature review and practical aspects on the management of oxaliplatin-associated toxicity.

  2012cited by this paper
• Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?

  2012cited by this paper
• Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.

  2012cited by this paper
• Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells.

  2012cited by this paper
• PEG‐liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase‐8

  2012cited by this paper
• Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.

  2012cited by this paper
• A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen

  2012cited by this paper
• Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy.

  2012cited by this paper
• Platinum anticancer drugs. From serendipity to rational design.

  2011cited by this paper
• Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting

  2011cited by this paper
• Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer

  2011cited by this paper
• PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.

  2011cited by this paper
• Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities.

  2010cited by this paper
• Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin

  2010cited by this paper
• Platinum–DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes

  2010cited by this paper
• Therapeutic effectiveness of slow-release PLGA-oxaliplatin microsphere on human colorectal tumor-bearing mice

  2010cited by this paper
• Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer.

  2010cited by this paper
• The status of platinum anticancer drugs in the clinic and in clinical trials.

  2010cited by this paper
• Polymeric drug delivery of platinum-based anticancer agents.

  2009cited by this paper
• ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.

  2009cited by this paper
• Nanocapsules of platinum anticancer drugs: development towards therapeutic use.

  2009cited by this paper
• The drug targeting and delivery approach applied to pt-antitumour complexes. A coordination point of view.

  2009cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

  2007cited by this paper
• Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study.

  2006cited by this paper
• Preclinical Efficacy and Pharmacokinetics of AP5346, A Novel Diaminocyclohexane-Platinum Tumor-Targeting Drug Delivery System

  2006cited by this paper
• Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent.

  2006cited by this paper
• Polymer conjugates as anticancer nanomedicines

  2006cited by this paper
• Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles.

  2005cited by this paper
• Selective tumor targeting by enhanced permeability and retention effect. Synthesis and antitumor activity of polyphosphazene-platinum (II) conjugates.

  2005cited by this paper
• Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.

  2005cited by this paper
• Synthesis, characterization, and tumor selectivity of a polyphosphazene-platinum(II) conjugate.

  2005cited by this paper
• 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex.

  2001cited by this paper
• Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.

  2001cited by this paper
• Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

  2000cited by this paper
• Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

  1996cited by this paper

• Drug delivery for platinum therapeutics.

  2025cites this paper
• A protracted war against cancer drug resistance

  2024cites this paper
• “Yin-Yang philosophy” for the design of anticancer drug delivery nanoparticles

  2024cites this paper
• Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy

  2023cites this paper